Synergistic inhibition of autophagy and neddylation pathways as a novel therapeutic approach for targeting liver cancer

Oncotarget. 2015 Apr 20;6(11):9002-17. doi: 10.18632/oncotarget.3282.

Abstract

Liver cancer is the second-most frequent cause of cancer death in the world and is highly treatment resistant. We reported previously that inhibition of neddylation pathway with specific NAE inhibitor MLN4924, suppressed the malignant phenotypes of liver cancer. However, during the process, MLN4924 induces pro-survival autophagy as a mechanism of drug resistance. Here, we report that blockage of autophagy with clinically-available autophagy inhibitors (e.g. chloroquine) significantly enhanced the efficacy of MLN4924 on liver cancer cells by triggering apoptosis. Mechanistically, chloroquine enhanced MLN4924-induced up-regulation of pro-apoptotic proteins (e.g. NOXA) and down-regulation of anti-apoptotic proteins. Importantly, the down-regulation of NOXA expression via siRNA silencing substantially attenuated apoptosis of liver cancer cells. Further mechanistic studies revealed that blockage of autophagy augmented MLN4924-induced DNA damage and reactive oxygen species (ROS) generation. The elimination of DNA damage or blockage of ROS production significantly reduced the expression of NOXA, and thereby attenuated apoptosis and reduced growth inhibition of liver cancer cells. Moreover, blockage of autophagy enhanced the efficacy of MLN4924 in an orthotopic model of human liver cancer, with induction of NOXA and apoptosis in tumor tissues. These findings provide important preclinical evidence for clinical investigation of synergistic inhibition of neddylation and autophagy in liver cancer.

Keywords: MLN4924; apoptosis; autophagy; chloroquine; neddylation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Apoptosis Regulatory Proteins / antagonists & inhibitors
  • Apoptosis Regulatory Proteins / biosynthesis
  • Autophagy / drug effects*
  • Carcinoma, Hepatocellular / drug therapy*
  • Carcinoma, Hepatocellular / metabolism
  • Cell Line, Tumor
  • Chloroquine / pharmacology*
  • Chloroquine / therapeutic use
  • Cyclopentanes / pharmacology*
  • Cyclopentanes / therapeutic use
  • DNA Damage
  • Drug Synergism
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / metabolism
  • Macrolides / pharmacology*
  • Molecular Targeted Therapy / methods*
  • NEDD8 Protein
  • Neoplasm Proteins / antagonists & inhibitors*
  • Neoplasm Proteins / biosynthesis
  • Protein Processing, Post-Translational / drug effects
  • Proto-Oncogene Proteins c-bcl-2 / biosynthesis
  • Pyrimidines / pharmacology*
  • Pyrimidines / therapeutic use
  • RNA, Small Interfering / metabolism
  • Random Allocation
  • Transfection
  • Ubiquitins / antagonists & inhibitors*
  • Xenograft Model Antitumor Assays

Substances

  • Antineoplastic Agents
  • Apoptosis Regulatory Proteins
  • Cyclopentanes
  • Macrolides
  • NEDD8 Protein
  • NEDD8 protein, human
  • Neoplasm Proteins
  • PMAIP1 protein, human
  • Proto-Oncogene Proteins c-bcl-2
  • Pyrimidines
  • RNA, Small Interfering
  • Ubiquitins
  • Chloroquine
  • bafilomycin A1
  • pevonedistat